Skip to content Skip to left sidebar Skip to footer

Monkeypox

Monkeypox Vaccine Deliveries Paused for Thanksgiving

Monkeypox Vaccine Deliveries Paused for Thanksgiving

Monkeypox vaccine deliveries will be paused during the week of Thanksgiving, November 21 – 25, 2022. The last delivery for monkeypox vaccine will be on Monday, November 21. 

Ordering will remain open this week until Thursday, by 5pm. Remember to submit your temperatures to tempcheck@phila.gov and complete a reconciliation of vaccine on hand for your order to be approved.

Click the button below to submit your order request for monkeypox vaccine.

Deliveries for monkeypox vaccine will resume on the week of November 28.

Thank you for keeping Philadelphia safe and healthy! If you have any questions, please contact Kenya Mack at Kenya.Mack@phila.gov

V-Safe for Monkeypox Vaccine: Survey to Assess Promotion Willingness and Perceived Barriers

V-Safe for Monkeypox Vaccine: Survey to Assess Promotion Willingness and Perceived Barriers

The Immunization Safety Office at CDC will soon be going live with a monkeypox module in CDC’s v-safe After Vaccination Health Checker. V-safe is a voluntary smartphone-based system that uses text messaging and web surveys to provide personalized and confidential health check-ins. Participants can tell CDC how they, or their child or dependent, feel after they receive a monkeypox vaccine.Based on the success of v-safe for COVID-19, the CDC has found that promoting and encouraging enrollment at the vaccine delivery site is the best way to make vaccine recipients aware of v-safe. Please fill out this short survey to assess willingness and perceived barriers to promotion of v-safe at your practice.

 

Temperature Reporting for Online Vaccine Ordering

Temperature Reporting for Online Vaccine Ordering

Temperature logs must be submitted on the same day as any order placed for federal vaccine (VFC, VFAAR, flu, COVID-19, or monkeypox)!

Temperature logs are to be uploaded in PhilaVax and emailed to tempcheck@phila.gov. The logs must show that the unit is within the appropriate temperature ranges and that there have been no alarms. This reporting guide can assist you in submitting your DDL temperature files.

For more information on ordering and how to upload your temperature log, please attend the next online ordering training on November 10, 2022 from 10:00AM – 11:00AM EST. Click the link below to register for the training.

If your site uses a privately purchased DDL or cannot upload in PhilaVax, please contact tempcheck@phila.gov.

Thank you for keeping Philadelphia safe and healthy! 

Become a Monkeypox Vaccine Provider

Become a Monkeypox Vaccine Provider 

Does your pharmacy see patients who are at a higher risk of monkeypox infection? If so, please consider becoming a Jynneos vaccine provider and help stop the spread of monkeypox infection. The current patient eligibility guidelines are as follows:
People who meet the following conditions: 
  • Gay, bisexual, transgender, non-binary, and other men who have sex with men, transgender, or non-binary persons
AND meet one of the following criteria: 
  • Have had multiple or anonymous sex partners in the last 14 days
  • Have had any newly diagnosed STI in the past 12 months, including gonorrhea, chlamydia, early syphilis, or HIV
  • Have recently attended or plan to attend any venue where anonymous sex or sex with multiple partners will occur (e.g. saunas, bathhouses, sex clubs, sex parties)
  • Have met recent partners or plan to meet new partners through social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas
Additionally, the following people are eligible: 
  • Sex workers (of any sex or gender), and/or
  • Anyone with known close contact (skin-to-skin) with someone with monkeypox in the past 14 days
If your patients are eligible for the monkeypox vaccine, we encourage you to enroll as a Jynneos vaccine provider. The Public Readiness and Emergency Preparedness Act (PREP) now includes liability coverage for pharmacists for countermeasures against smallpox (variola virus), monkeypox virus, and other orthopoxviruses. Read the monkeypox PREP FAQ.
Note: this vaccine is administered intradermally, and may require some additional training of staff to administer appropriately.
Please complete the enrollment form if your site is interested in offering Jynneos vaccine.
Please reach out to Kenya Mack at Kenya.Mack@phila.gov or Jillian Brown at Jillian.Brown@phila.gov with any questions.

Monkeypox Vaccine Update: Expanded Eligibility

Monkeypox Vaccine Update: Expanded Eligibility

Monkeypox vaccine eligibility requirements have recently been updated. The following people are eligible to be vaccinated against monkeypox in Philadelphia:• Gay, bisexual, transgender, non-binary, and other men who have sex with men, transgender, or non-binary persons

IF they meet ONE of the following criteria:• Have had multiple or anonymous sex partners in the last 14 days• Have had any newly diagnosed STI in the past 12 months, including gonorrhea, chlamydia, early syphilis, or HIV• Have recently attended or plan to attend any venue where anonymous sex or sex with multiple partners will occur (e.g. saunas, bathhouses, sex clubs, sex parties)• Have met recent partners or plan to meet new partners through social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas   Additionally, the following people are eligible:• Sex partners (of any sex or gender) of people who meet the above criteria• Sex workers (of any sex or gender)
• Anyone with known close contact (skin-to-skin) with someone with monkeypox in the past 14 days
Thank you for keeping Philadelphia safe and healthy! If you have any questions about these updates, please contact vaccines@phila.gov.

Become a Monkeypox Vaccine Provider

Become a Monkeypox Vaccine Provider

Do you see patients who are at a higher risk of monkeypox infection? If so, please consider becoming a Jynneos vaccine provider and help stop the spread of monkeypox infection. The current patient eligibility guidelines are as follows:

People who meet ALL of the following conditions: 
  • Gay, bisexual, transgender, non-binary, and other men who have sex with men, transgender, or non-binary persons

AND meet one of the following criteria:

  • Have had multiple or anonymous sex partners in the last 14 days
  • Have had any newly diagnosed STI in the past 12 months, including gonorrhea, chlamydia, early syphilis, or HIV
  • Have recently attended or plan to attend any venue where anonymous sex or sex with multiple partners will occur (e.g. saunas, bathhouses, sex clubs, sex parties) in the next 30 days
  • Have met recent partners or plan to meet new partners in the next 30 days through social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas
Additionally, the following people are eligible:
  • Sex workers (of any sex or gender), and/or
  • Anyone with known close contact (skin-to-skin) with someone with monkeypox in the past 14 days
If your site sees patients who are eligible for the monkeypox vaccine, we encourage you to enroll as a Jynneos vaccine provider. Sites are not required to see non-patients, but we do encourage providers to offer walk-in vaccine availability and if possible, vaccinate non-patients.

Note: this vaccine is administered intradermally, and may require some additional training of staff to administer appropriately.Please complete the enrollment form if your site is interested in offering Jynneos vaccine.

Please reach out to Kenya Mack at Kenya.Mack@phila.gov or Jillian Brown at Jillian.Brown@phila.gov with any questions.

Monkeypox Vaccine Update: Expanded Eligibility & Second Doses

Monkeypox Vaccine Update: Expanded Eligibility & Second Doses

There is now vaccine supply to begin administering a complete two-dose Jynneos vaccine series to each individual who is eligible for vaccine.

Updates

Eligibility for a first dose now includes:
• People of all ages. Subcutaneous administration continues to be required for those <18.
• People with a history of STI in the past 12 months, as well as individuals who plan to have multiple or anonymous sex partners, or those plan to meet new sexual partners via social media.

Eligibility for a second dose now includes:
• People who have received a first Jynneos vaccine dose through either intradermal or subcutaneous administration. This dose should be given intradermally to those 18 and older unless there is a contraindication.

Eligibility has also expanded to include those with a history of STI in the past 12 months (from 6 months previously) and to start offering preexposure prophylaxis to people at high risk for becoming infected. The interval between doses for both subcutaneous and intradermal injections is at minimum 28 days. Individuals who test positive for monkeypox after their first dose should not receive a second dose of vaccine. Individuals whose second doses have been delayed do not need to restart the two-dose vaccine series.

There is no age requirement for Jynneos vaccine eligibility, although those less than 18 years of age must receive the vaccine subcutaneously. Individuals 18 and older will be given intradermal vaccination, regardless of which method was used for the first vaccine, unless there is a contraindication.

Complete eligibility criteria include:

People who meet the following condition:

• Gay, bisexual, transgender, non-binary, and other men who have sex with men, transgender, or non-binary persons

AND meet ONE of the following criteria:

• Have had multiple or anonymous sex partners in the last 14 days
• Have had any newly diagnosed STI in the past 12 months, including gonorrhea, chlamydia, early syphilis, or HIV
• Have recently attended or plan to attend any venue where anonymous sex or sex with multiple partners will occur (e.g. saunas, bathhouses, sex clubs, sex parties) in the next 30 days
• Have met recent partners or plan to meet new partners in the next 30 days through social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas

Additionally, the following people are eligible:

• Sex workers (of any sex or gender), and/or
• Anyone with known close contact (skin-to-skin) with someone with monkeypox in the past 14 days

When using an intradermal strategy, there may be unused doses in a single vial. All efforts should be made to give doses to the above eligible individuals. If there are doses that would go wasted, they may be given to other individuals not included in the above criteria. Healthcare workers directly involved in testing and examining those with possible monkeypox illness and staff involved in environmental cleaning and disinfection protocols should be prioritized.

Thank you for keeping Philadelphia safe and healthy! If you have any questions about these updates, please contact vaccines@phila.gov.

Monkeypox Testing, Treatment, and Vaccine Resources

Monkeypox Testing, Treatment, and Vaccine Resources

Following PDPH’s information session on Wednesday, August 17, we have included the slides from our presentation and follow up resources on monkeypox testing and treatment.

Information for Healthcare Providers on Obtaining and Using TPOXX (Tecovirimat) for Treatment of Monkeypox

CDC, in partnership with FDA, has made it easier for healthcare providers to provide tecovirimat (TPOXX) treatment to patients with monkeypox under EA-IND. The streamlined process reduces the number of required forms and gives patients the option to see their doctor virtually. View the CDC’s full guidance.
If you are using CDC IRB: CDC IRB serves as the central IRB for review and approval. Facilities may elect to rely on the CDC IRB for centralized review and approval by submitting a request to the CDC’s Human Research Protection Office within 7 calendar days of tecovirimat treatment at your facility. CDC will promptly document an agreement in writing using the CDC IRB Authorization Agreement (Sample Template) [4 MB, 2 pages] which must be signed by both parties.For institutions that use EPIC, here is where the CDC TPOXX intake form (Form A) can be downloaded. When you open the file, you can copy it into an Epic smart phrase, and then just make sure the fields that are being pulled in with the smart phrases match the fields that we have in your version of EPIC. There were a couple of small discrepancies (e.g. our epic uses @DEPTPHN@ instead of @DEPTPHONE@ for the department phone numbers). We also had to make a few “Smart lists” by hand (like where the form had {tecovirimat reason:45613} we had to recreate that based off the CDC form). You can upload the outcome form into Epic and share it with any providers who might use it.

Monkeypox Update: Second Doses

Monkeypox Update: Second Doses

PDPH is recommending that providers who are currently offering monkeypox vaccine to their patients and individuals at highest risk to begin offering second doses of the JYNNEOS vaccine to patients who have received their first dose intradermally. The second dose is recommended 28 days after the first dose.Currently, it is not recommended that patients who received their first dose subcutaneously be recalled for a second dose. Recommendations for when and at what interval subcutaneous doses should be administered will be shared soon.Patients should be reminded protection from monkeypox is not immediate with one dose. Two doses of the JYNNEOS vaccine are required for full protection and maximum immunity is reached 14 days after the second dose. One dose will provide some protection 14 days after vaccinations, but people should still continue to take precautions against monkeypox during this time.More information is available from PDPH at https://bit.ly/PHLMonkeypoxInfo.
Providers will need to enter order requests by 5 pm on Mondays. If your request is approved, you can expect to receive MPX doses Wednesday or Thursday following your request date.

For further questions, email vaccines@phila.gov.